The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

November 22, 2024

Study Completion Date

December 23, 2024

Conditions

NAFLDNonalcoholic Fatty LiverNASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

LUM-201

LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.

Trial Locations (1)

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER